Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at European Life Sciences CEO Forum Fapon Biopharma unveiled its cutting-edge CD3/TCR VHH TCE platform at the European Life Sciences CEO Forum, aiming to revolutionize T-cell engagement technologies.

Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at European Life Sciences CEO Forum #USA #Zurich #Fapon_Biopharma #TCE_Platform #CD3/TCR_VHH

Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at CEO Forum Discover the cutting-edge CD3/TCR VHH TCE platform that Fapon Biopharma showcased at the European Life Sciences CEO Forum, enhancing cancer treatment.

Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at CEO Forum #Switzerland #Zurich #Fapon_Biopharma #TCE_Platform #CD3/TCR_VHH

Antengene's 2025 Interim Results Showcase Promising Advances in Cancer Treatments and Innovative Technologies Antengene Corporation released its interim results for 2025, highlighting progress in clinical trials and new treatment strategies for cancer therapies.

Antengene's 2025 Interim Results Showcase Promising Advances in Cancer Treatments and Innovative Technologies #Shanghai #Antengene #ATG-022 #TCE_Platform